Navigation Links
Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer
Date:8/4/2010

CAMBRIDGE, Mass., Aug. 4 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the appointment of Antonin (Tony) de Fougerolles, Ph.D., as Chief Scientific Officer. Dr. de Fougerolles’ appointment as Tolerx’s CSO will provide leadership for the company’s research and early-stage product development programs involving novel therapies based on T cell modulation.  Dr. de Fougerolles brings to Tolerx more than 15 years of biotech R&D experience and expertise in immunology. He will direct the company’s R&D activities and strengthen Tolerx’s leadership in T cell immunology.

(Photo: http://photos.prnewswire.com/prnh/20100804/NE45601 )

(Photo: http://www.newscom.com/cgi-bin/prnh/20100804/NE45601 )

"We are delighted and enthusiastic about Tony joining us as CSO at this pivotal time, when Tolerx is poised to make substantial progress in expanding our pipeline of drug candidates based on T cell modulation," said Dr. Douglas J. Ringler, Chief Executive Officer of Tolerx. "Tony brings world-class R&D experience from well-known biotech companies, and his skills and expertise will extend our scientific leadership in T cell modulation and help lead Tolerx through our next stage of growth as we broaden our pipeline of innovative T cell therapies.”

Prior to joining Tolerx, Dr. de Fougerolles was Vice President, Research, Immunology, Metabolic, and Viral Disease at Alnylam Pharmaceuticals.  Dr. de Fougerolles joined Alnylam in 2003, holding positions of increasing responsibility and playing a key role in the development of several research programs, including those with Alnylam partners Novartis and Roche. Before joining Alnylam, he served as a Principal Scientist at Biogen, Inc. (now Biogen Idec Inc.), where he had worked since 1998. At Biogen, Dr. de Fougerolles worked on several immunology/inflammation-based programs and led research teams working to develop antibody-based therapeutics. Dr. de Fougerolles earned his Ph.D. in Immunology from Harvard University, and was a Research Fellow at the Laboratory of Molecular Biology in Cambridge, England.

“I am very excited to join Tolerx at this time of transformational growth, and believe the depth and quality of Tolerx’s team and expertise in T cell modulation position the company to significantly advance and build its pipeline of new therapeutics,” said Dr. de Fougerolles. “I am particularly enthusiastic about helping to advance the product pipeline and playing a key role in developing novel therapies that are on the cutting edge of exploiting the science of T cell activity to treat autoimmune diseases and cancer in fundamentally new ways."

About Tolerx

Tolerx, Inc., a world leader in the understanding of T cell function, is developing novel therapies intended to treat autoimmune diseases, diabetes, and cancer by specifically modulating T cell activity.  The company’s pipeline includes its lead candidate, otelixizumab, a targeted T cell immunomodulator in Phase 3 development for the treatment of type 1 diabetes that is partnered with GlaxoSmithKline.  TRX1, a Phase 1 candidate, is a nonlytic anti-CD4 antibody that is being developed for the treatment of aberrant or untoward humoral immune responses.  The company also has three pre-clinical candidates, TRX518, TRX585, and TRX385, that enhance immune responses and as such are being evaluated for potential benefit in the treatment of cancer and chronic infections. Tolerx is a privately held company headquartered in Cambridge, MA USA.  For more information, please visit www.tolerrx.com.


'/>"/>
SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
2. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
3. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
4. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
5. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
6. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
7. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
8. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
9. InQ Biosciences Appoints John Ryder as Senior Vice President, Sales & Marketing
10. Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
11. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... 2017  ivWatch LLC, a medical device company focused ... therapy, is pleased to announce it was the Bronze ... Supplies and Equipment at the 2017 Medical Design Excellence ... industry. The award was presented by Medical Device and ... in New York during MD&M ...
(Date:6/14/2017)... 2017  In 2016, Embodied Labs took ... competition and came away with $25,000 in seed-fund investment. ... Forbes as "entering the life of another" and by ... "empathy to medical professionals in an entirely new dimension." ... a finalist for the Department of Education,s EdSimChallenge, where ...
(Date:6/12/2017)... -- Kineta, Inc., a biotechnology company focused on the development ... of R&D and Head of Virology Kristin Bedard has been ... Northwest and Beyond meeting sponsored by Life Science Washington. ... 8:30-10:30 AM PDT at the Agora Conference Center in ... will be joined by other leaders in infectious disease research ...
Breaking Medicine Technology:
(Date:6/27/2017)... ... June 27, 2017 , ... Salucro, ... of the health care industry’s hospitals and provider groups, has announced that it ... select customers. Parasail Health is a San Francisco health-finance startup that has launched ...
(Date:6/27/2017)... ... June 27, 2017 , ... A January 18th article on medGadget ... $6.81 billion by the year 2024 according to a new report. The article also ... made from titanium. Los Angeles area clinic Beverly Hills Periodontics & Dental Implant Center ...
(Date:6/27/2017)... Portland, Ore. (PRWEB) , ... June 27, 2017 ... ... Provider (CSP), today announced the expansion of Atmosera Managed Azure Services . ... now includes enhancements in support of the company’s growing customer base. Atmosera’s next ...
(Date:6/27/2017)... ... ... Today, June 27th is PTSD Awareness Day. Over half a million U.S. ... care due to lack of effective treatments, fear of stigma or insufficient government resources. ... veterans are at an increased risk for self-destructive behavior, including alcohol/drug abuse, depression, anxiety ...
(Date:6/26/2017)... ... ... Torrance dentist, Dr. Robert Mondavi DDS , is now offering comprehensive ... a person’s appearance. A healthy, radiant smile can make a person look more attractive, ... have the smile of their dreams with cosmetic dentistry. , “The field of dentistry ...
Breaking Medicine News(10 mins):